Lumira Ventures is the famous VC, which was founded in 1989. The main department of described VC is located in the Toronto. The fund was located in North America if to be more exact in Canada.
The overall number of key employees were 12.
The top amount of exits for fund were in 2019. This Lumira Ventures works on 12 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Lumira Ventures, startups are often financed by Fonds de solidaritu00e9 FTQ, Arboretum Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Fonds de solidaritu00e9 FTQ, Aperture Venture Partners, SV Health Investors. In the next rounds fund is usually obtained by M. H. Carnegie & Co., Fonds de solidaritu00e9 FTQ, Arboretum Ventures.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Cardiac Dimensions, Thrasos, Celtaxsys Among the most popular fund investment industries, there are Biopharma, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
Cyrano Therapeutics | $9M | 16 Jan 2024 | Washington, District of Columbia, United States | ||
Specific Biologics | 10 Oct 2023 | Ontario, California, United States | |||
Deka Biosciences | $20M | 28 Sep 2023 | Washington, District of Columbia, United States | ||
PIC Therapeutics | $35M | 19 Oct 2022 | Massachusetts, United States | ||
Damona Pharmaceuticals | $5M | 26 Sep 2022 | Toronto, Ontario, Canada | ||
Congruence Therapeutics | $50M | 08 Feb 2022 | Montréal, Quebec, Canada | ||
Deka Biosciences | $21M | 01 Jan 2022 | Washington, District of Columbia, United States | ||
Specific Biologics | 16 Dec 2021 | Ontario, California, United States |
– Antios Therapeutics from San Diego, CA announced the successful completion of a $96m Series B financing.
– The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital.
– Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.
– XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, today announced the closing of an additional $22.6 million financing.
– Fountain Healthcare Partners led the oversubscribed financing joined by new investors Longwood Fund and Lumira Ventures. All existing institutional investors including Sofinnova Investments and LSP (Life Sciences Partners) participated in the financing.
– The additional financing builds upon XyloCor’s 2018 Series A financing round, bringing total investment in the company to $41.9 million to date.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
Cyrano Therapeutics | $9M | 16 Jan 2024 | Washington, District of Columbia, United States | ||
Specific Biologics | 10 Oct 2023 | Ontario, California, United States | |||
Deka Biosciences | $20M | 28 Sep 2023 | Washington, District of Columbia, United States | ||
PIC Therapeutics | $35M | 19 Oct 2022 | Massachusetts, United States | ||
Damona Pharmaceuticals | $5M | 26 Sep 2022 | Toronto, Ontario, Canada | ||
Congruence Therapeutics | $50M | 08 Feb 2022 | Montréal, Quebec, Canada | ||
Deka Biosciences | $21M | 01 Jan 2022 | Washington, District of Columbia, United States | ||
Specific Biologics | 16 Dec 2021 | Ontario, California, United States |
